Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Acasti Pharma Inc ACST

Acasti Pharma Inc. is a Canada-based late-stage biopharma company with drug candidates addressing rare and orphan diseases. The Company is targeting three underserved orphan diseases: GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (SAH), a rare and life-threatening medical emergency, in which bleeding occurs over the surface of the brain in the subarachnoid space between the brain and skull; GTX-102, an oral mucosal spray targeting ataxia-telangiectasia (A-T), a progressive, neurodegenerative genetic disease that primarily impacts children causing severe disability; and GTX-101, a topical spray, targeting postherpetic neuralgia, a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles). The Company’s clinical assets have each been granted Orphan Drug Designation by the FDA, which provides seven years of marketing exclusivity post-launch in the United States, and additional intellectual property protection.


NDAQ:ACST - Post by User

Comment by EternalPonzion Mar 11, 2020 8:56am
73 Views
Post# 30792351

RE:RE:RE:RE:RE:RE:Here’s the problem

RE:RE:RE:RE:RE:RE:Here’s the problem
Yes they have about $30 million CDN (not US) and hopefully they will manage these financial resources well. However, they will need much more financing to successfully launch the product. The fact that the company says they have no plans to do something (or not) doesn't make it so. Many companies say and do things all the time that was unexpected in their self-interest. For example, one day a company adamantly states they are not cutting the dividend, the next day the dividend is slashed. Happens more often than most realize. Self-interest is the single most driving factor that dictates decision making. It applies to you, to me, to everyone. More often than not lying, or not revealing all the facts, is required to ensure this self-interest remains viable. Look, I hope things will work out with ACST, but people should really stop having all these pie in the sky expectations of how things are likely to progress. There is a saying; 'Don't count your chickens...'
<< Previous
Bullboard Posts
Next >>